Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver

Inclusion Criteria: * Histologically confirmed metastatic uveal melanoma in the liver; patients must have at least one measurable liver metastasis that is \>= 10 mm in longest diameter by computed tomography (CT) scan or magnetic resonance imaging (MRI) * The total volume of the tumors must be less than 50% of the liver volume * Willingness and ability to give informed consent * Agreement to access archival tissue or agreement for tumor biopsy prior to treatment * Eastern Cooperative Oncology Group (ECOG) performance status of 0, or 1 * Serum creatinine =\< 2.0 mg/dl * Granulocyte count \>= 1000/mm\^3 * Platelet count \>= 100,000/mm\^3 * Bilirubin =\< 2.0 mg/ml * Albumin \>= 3.0 g/dl * Prothrombin time (PT)/partial thromboplastin time (PTT) less than 1.5 times normal * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than 3 x upper limit of normal (ULN) * Alkaline phosphatase less than 1.5 times ULN (grade 1) * Women must not be pregnant or breast-feeding * Women of child-bearing potential must use at least two other accepted and effective methods of contraception and/or to abstain from sexual intercourse for at least 23 weeks after the last dose of nivolumab and/or ipilimumab and sexually active males must use at least two other accepted and effective methods of contraception and/or to abstain from sexual intercourse for at least 31 weeks after the last dose of nivolumab and/or ipilimumab Exclusion Criteria: * Failure to meet any of the criteria se…